PT - JOURNAL ARTICLE AU - Barbehenn, Alton AU - Shi, Lei AU - Shao, Junzhe AU - Hoh, Rebecca AU - Hartig, Heather M. AU - Pae, Vivian AU - Sarvadhavabhatla, Sannidhi AU - Donaire, Sophia AU - Sheikhzadeh, Caroline AU - Milush, Jeffrey AU - Laird, Gregory M. AU - Mathias, Mignot AU - Ritter, Kristen AU - Peluso, Michael J. AU - Martin, Jeffrey AU - Hecht, Frederick AU - Pilcher, Christopher AU - Cohen, Stephanie E. AU - Buchbinder, Susan AU - Havlir, Diane AU - Gandhi, Monica AU - Henrich, Timothy J. AU - Hatano, Hiroyu AU - Wang, Jingshen AU - Deeks, Steven G. AU - Lee, Sulggi A. TI - Rapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease AID - 10.1101/2024.03.27.24304867 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.27.24304867 4099 - http://medrxiv.org/content/early/2024/08/22/2024.03.27.24304867.short 4100 - http://medrxiv.org/content/early/2024/08/22/2024.03.27.24304867.full AB - Despite antiretroviral therapy (ART), HIV persists in latently-infected cells (“the reservoir”) which decay slowly over time. Here, leveraging >500 longitudinal samples from 67 people with HIV (PWH) treated during acute infection, we developed a novel mathematical model to predict reservoir decay from peripheral CD4+ T cells. Nonlinear generalized additive models demonstrated rapid biphasic decay of intact DNA (week 0-5: t1/2∼2.83 weeks; week 5-24: t1/2∼15.4 weeks) that extended out to 1 year. These estimates were ∼5-fold faster than prior decay estimates among chronic treated PWH. Defective DNA had a similar biphasic pattern, but data were more variable. Predicted intact and defective decay rates were faster for PWH with earlier timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. These data add to our limited understanding of HIV reservoir decay at the time of ART initiation, informing future curative strategies targeting this critical time.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02656511Funding StatementThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent, and the institutional review board of University of California, San Fransisco approved the research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.